Gums, Aging, and the Omega-3 Connection

Key takeaways

• In a year-long trial of people with significant gum inflammation, a combination of omega-3 fatty acids and low-dose aspirin worked as well as a standard antibiotic protocol.
• Roughly 58% of people in the antibiotic group reached the treatment goal, compared with 57.7% in the omega-3-plus-aspirin group — nearly identical results, and both far ahead of the 23.1% seen with the baseline cleaning procedure alone.
• The benefits from omega-3 and aspirin persisted for six months after supplementation stopped, hinting that the approach may reset how the body handles inflammation rather than just suppressing it temporarily.

• Gum health is increasingly seen as a window into whole-body inflammation, one of the core biological processes tied to how well — and how fast — we age.

Researchers set out to test whether a nutrient-based approach could stand in for antibiotics in people with advanced gum issues — a condition where deep pockets form below the gumline and act as reservoirs for problem bacteria. Everyone in the trial received the same baseline procedure, a deep cleaning that clears bacterial buildup from those pockets. From there, participants were split into four groups: a placebo group, an antibiotic group, an omega-3-plus-aspirin group, and a group that combined both approaches.

After a year, the omega-3 and aspirin group came within half a percentage point of matching the antibiotic group on the primary measure of success. The combination group — antibiotics plus omega-3 and aspirin together — didn't outperform either strategy alone, which surprised the research team going in.

How do fatty acids and aspirin work together?

The logic behind this pairing comes down to how the body resolves inflammation rather than just blocking it. Omega-3 fatty acids feed into the production of specialized molecules that actively help inflammation wind down and support tissue repair, a different mechanism than conventional anti-inflammatory approaches that mainly block specific pathways. Low-dose aspirin appears to boost the production of those same inflammation-resolving molecules, which is likely why the two compounds performed better together than either would be expected to alone.

Early work in animal models had already hinted that omega-3 could reduce inflammation and tissue loss in the mouth, especially when paired with physical activity. This human trial is the first strong signal that the same principle might translate to people.

What do gums have to do with longevity?

The most interesting piece of this study isn't really about oral health in isolation — it's about inflammation resolution as a lever the body can be nudged to use more effectively. Chronic, low-grade inflammation is a thread that runs through many aspects of aging, and this trial offers a rare human data point showing that a simple nutrient combination can meaningfully shift an inflammatory process, with effects that outlasted the treatment period itself.

There's also a public-health angle worth noting: reducing unnecessary antibiotic use helps preserve their effectiveness for situations where they're truly needed. A dietary and supplement-based option that performs comparably gives people, and their care providers, more flexibility — particularly useful for anyone who can't tolerate antibiotics well.

The takeaway

This was one trial, and the researchers themselves describe it as a step forward rather than a green light to swap out established care. But the core finding — that a combination of omega-3 and low-dose aspirin nearly matched antibiotics on a hard clinical outcome, with effects that lingered for months afterward — is a compelling data point for anyone tracking how nutrition intersects with the body's inflammatory machinery over the long run.

It's a reminder that some of the most promising longevity levers are often familiar compounds, used deliberately, aimed at a process — inflammation resolution — that shows up again and again across the aging story.

References:

Nidia C. Castro dos Santos et al. Immunomodulators, associated or not with systemic antibiotics, to treat periodontitis: A 1-year multicenter, placebo-controlled, double-blind, randomized clinical trial. Journal of Periodontology, 2026; 97 (7): 1454. DOI: 10.1002/jper.70081. Reported by ScienceDaily, August 30, 2026.